Timothy S. Shilton
Vorstandsvorsitzender bei ReGen Therapeutics Ltd.
Profil
Timothy S.
Shilton is currently the Chief Executive Officer & Director at ReGen Therapeutics Ltd.
since 2011 and the Marketing Director at Phairson Medical Ltd.
since 1996.
He previously worked as the Development Director at ReGen Therapeutics Plc from 2000 to 2011 and as a Director at Alexander David Investments Plc in 2011.
Mr. Shilton completed his undergraduate degree from the University of Surrey in 1979.
Aktive Positionen von Timothy S. Shilton
| Unternehmen | Position | Beginn |
|---|---|---|
Phairson Medical Ltd.
 Phairson Medical Ltd. Miscellaneous Commercial ServicesCommercial Services Phairson Medical Ltd. researches and develops novel biopharmaceutical products and devices. The private company is based in London, UK. | Vertrieb & Marketing | 10.11.2010 |
ReGen Therapeutics Ltd.
 ReGen Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Ltd. manufactures and distributes pharmaceutical products. The company was founded in February 1998 and is headquartered in in London, the United Kingdom. | Vorstandsvorsitzender | 01.02.2011 |
Ehemalige bekannte Positionen von Timothy S. Shilton
| Unternehmen | Position | Ende |
|---|---|---|
ReGen Therapeutics Plc
 ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 23.02.2011 |
Alexander David Investments Plc
 Alexander David Investments Plc Financial ConglomeratesFinance Alexander David Investments Plc operates as an investment company. Its investment targets are small cap and special opportunities with a current bias towards basic resources and oil and gas sectors. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 10.02.2011 |
Ausbildung von Timothy S. Shilton
| University of Surrey | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Health Technology |
Phairson Medical Ltd.
Phairson Medical Ltd. Miscellaneous Commercial ServicesCommercial Services Phairson Medical Ltd. researches and develops novel biopharmaceutical products and devices. The private company is based in London, UK. | Commercial Services |
ReGen Therapeutics Ltd.
ReGen Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Ltd. manufactures and distributes pharmaceutical products. The company was founded in February 1998 and is headquartered in in London, the United Kingdom. | Health Technology |
Alexander David Investments Plc
Alexander David Investments Plc Financial ConglomeratesFinance Alexander David Investments Plc operates as an investment company. Its investment targets are small cap and special opportunities with a current bias towards basic resources and oil and gas sectors. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | Finance |
